全文获取类型
收费全文 | 1114篇 |
免费 | 108篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 30篇 |
妇产科学 | 21篇 |
基础医学 | 128篇 |
口腔科学 | 6篇 |
临床医学 | 103篇 |
内科学 | 205篇 |
皮肤病学 | 18篇 |
神经病学 | 61篇 |
特种医学 | 37篇 |
外科学 | 259篇 |
综合类 | 12篇 |
一般理论 | 1篇 |
预防医学 | 108篇 |
眼科学 | 26篇 |
药学 | 94篇 |
中国医学 | 8篇 |
肿瘤学 | 116篇 |
出版年
2023年 | 11篇 |
2022年 | 27篇 |
2021年 | 62篇 |
2020年 | 26篇 |
2019年 | 38篇 |
2018年 | 52篇 |
2017年 | 35篇 |
2016年 | 44篇 |
2015年 | 53篇 |
2014年 | 72篇 |
2013年 | 84篇 |
2012年 | 102篇 |
2011年 | 79篇 |
2010年 | 49篇 |
2009年 | 36篇 |
2008年 | 57篇 |
2007年 | 63篇 |
2006年 | 43篇 |
2005年 | 38篇 |
2004年 | 33篇 |
2003年 | 33篇 |
2002年 | 36篇 |
2001年 | 13篇 |
2000年 | 13篇 |
1999年 | 15篇 |
1998年 | 8篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 5篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1965年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有1235条查询结果,搜索用时 31 毫秒
51.
52.
Brandon A. Mahal David R. Ziehr Ayal A. Aizer Andrew S. Hyatt Jesse D. Sammon Marianne Schmid Toni K. Choueiri Jim C. Hu Christopher J. Sweeney Clair J. Beard Anthony V. D׳Amico Neil E. Martin Christopher Lathan Simon P. Kim Quoc-Dien Trinh Paul L. Nguyen 《Urologic oncology》2014,32(8):1285-1291
ObjectivesTreating high-risk prostate cancer (CaP) with definitive therapy improves survival. We evaluated whether having health insurance reduces racial disparities in the use of definitive therapy for high-risk CaP.Materials and methodsThe Surveillance, Epidemiology, and End Results Program was used to identify 70,006 men with localized high-risk CaP (prostate-specific antigen level >20 ng/ml or Gleason score 8–10 or stage>cT3a) diagnosed from 2007 to 2010. We used multivariable logistic regression to analyze the 64,277 patients with complete data to determine the factors associated with receipt of definitive therapy.ResultsCompared with white men, African American (AA) men were significantly less likely to receive definitive treatment (adjusted odds ratio [AOR] = 0.60; 95% CI: 0.56–0.64; P<0.001) after adjusting for sociodemographics and known CaP prognostic factors. There was a significant interaction between race and insurance status (Pinteraction = 0.01) such that insurance coverage was associated with a reduction in racial disparity between AA and white patients regarding receipt of definitive therapy. Specifically, the AOR for definitive treatment for AA vs. white was 0.38 (95% CI: 0.27–0.54, P<0.001) among uninsured men, whereas the AOR was 0.62 (95% CI: 0.57–0.66, P<0.001) among insured men.ConclusionsAA men with high-risk CaP were significantly less likely to receive potentially life-saving definitive treatment when compared with white men. Having health insurance was associated with a reduction in this racial treatment disparity, suggesting that expansion of health insurance coverage may help reduce racial disparities in the management of aggressive cancers. 相似文献
53.
Praful Ravi Pierre I. Karakiewicz Florian Roghmann Giorgio Gandaglia Toni K. Choueiri Mani Menon Rana R. McKay Paul L. Nguyen Jesse D. Sammon Shyam Sukumar Briony Varda Steven L. Chang Adam S. Kibel Maxine Sun Quoc-Dien Trinh 《Urologic oncology》2014,32(8):1333-1340
ObjectiveTo examine the burden of mental health issues (MHI), namely anxiety, depressive disorders, and suicide, in a population-based cohort of older men with localized prostate cancer and to evaluate associations with primary treatment modality.Patients and methodsA total of 50,856 men, who were 65 years of age or older with clinically localized prostate cancer diagnosed between 1992 and 2005 and without a diagnosis of mental illness at baseline, were abstracted from the Surveillance, Epidemiology, and End Results–Medicare database. The primary outcome of interest was the development of MHI (anxiety, major depressive disorder, depressive disorder not elsewhere classified, neurotic depression, adjustment disorder with depressed mood, and suicide) after the diagnosis of prostate cancer.ResultsA total of 10,389 men (20.4%) developed MHI during the study period. Independent risk factors for MHI included age≥75 years (hazard ratio [HR] = 1.29); higher comorbidity (Charlson comorbidity index≥3, HR = 1.63); rural hospital location (HR = 1.14); being single, divorced, or widowed (HR = 1.12); later year of diagnosis (HR = 1.05); and urinary incontinence (HR = 1.47). Black race (HR = 0.79), very high-income status (HR = 0.87), and definitive treatment (radical prostatectomy [RP], HR = 0.79; radiotherapy [RT], HR= 0.85, all P<0.001) predicted a lower risk of MHI. The rates of MHI at 10 years were 29.7%, 29.0%, and 22.6% in men undergoing watchful waiting (WW), RT, and RP, respectively.ConclusionOlder men with localized prostate cancer had a significant burden of MHI. Men treated with RP or RT were at a lower risk of developing MHI, compared with those undergoing WW, with median time to development of MHI being significantly greater in those undergoing RP compared with those undergoing RT or WW. 相似文献
54.
Becky B. Trinh Nicole R. Jackson Adam T. Hauch Tian Hu Emad Kandil 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2014,18(4)
Background:
Robotic approaches have become increasingly used for colorectal surgery. The aim of this study is to examine the safety and efficacy of robotic colorectal procedures in an adult population.Study Design:
A systematic review of articles in both PubMed and Embase comparing laparoscopic and robotic colorectal procedures was performed. Clinical trials and observational studies in an adult population were included. Approaches were evaluated in terms of operative time, length of stay, estimated blood loss, number of lymph nodes harvested, and perioperative complications. Mean net differences and odds ratios were calculated to examine treatment effect of each group.Results:
Two hundred eighteen articles were identified, and 17 met the inclusion criteria, representing 4,342 patients: 920 robotic and 3,422 in the laparoscopic group. Operative time for the robotic approach was 38.849 minutes longer (95% confidence interval: 17.944 to 59.755). The robotic group had lower estimated blood loss (14.17 mL; 95% confidence interval: –27.63 to –1.60), and patients were 1.78 times more likely to be converted to an open procedure (95% confidence interval: 1.24 to 2.55). There was no difference between groups with respect to number of lymph nodes harvested, length of stay, readmission rate, or perioperative complication rate.Conclusions:
The robotic approach to colorectal surgery is as safe and efficacious as conventional laparoscopic surgery. However, it is associated with longer operative time and an increased rate of conversion to laparotomy. Further prospective randomized controlled trials are warranted to examine the cost-effectiveness of robotic colorectal surgery before it can be adopted as the new standard of care. 相似文献55.
56.
57.
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study 总被引:14,自引:0,他引:14
Gish RG Trinh H Leung N Chan FK Fried MW Wright TL Wang C Anderson J Mondou E Snow A Sorbel J Rousseau F Corey L 《Journal of hepatology》2005,43(1):60-66
BACKGROUND/AIMS: The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B. METHODS: Eligible patients were randomized in a double-blind, parallel study to evaluate 25, 100 or 200 mg once daily doses of emtricitabine for 48 weeks. Patients were then followed for an additional 48 weeks on open-label 200 mg emtricitabine. Serum HBV DNA, ALT, and hepatitis B serology were measured at regular intervals over the 2 years. Resistance surveillance was performed after 1 and 2 years on viremic samples, i.e. > 4700 copies/mL. RESULTS: Emtricitabine was well tolerated and produced a dose proportional antiviral response. After 2 years, 53% of the patients had serum HBV DNA < or = 4700 copies/mL, 33% seroconverted to anti-HBe and 85% had normal ALT. Eighteen percent of the patients who had received 200 mg emtricitabine for 2 years developed resistance mutations. CONCLUSIONS: Emtricitabine was well tolerated and demonstrated a potent antiviral response for up to 2 years in patients with chronic hepatitis B infection. Based on these data, 200 mg emtricitabine once daily was chosen as the optimal dose for future hepatitis B studies. 相似文献
58.
Importance of catalase in the disposal of hydrogen peroxide within human erythrocytes 总被引:2,自引:1,他引:2
The catalase within normal, intact human erythrocytes was completely inactivated with amino triazole. The rate of 14CO2 evolution, when the cells were subsequently incubated with 14C-labeled glucose, provided a measure of the rate at which NADPH was being oxidized by the glutathione peroxidase/reductase system for the disposal of H2O2. This rate was determined in control cells and in catalase-inactivated cells while the cells were exposed to H2O2, which was generated at various constant and predetermined rates by glucose oxidase. The results indicated that catalase handles approximately half of the generated H2O2. The glutathione peroxidase/reductase mechanism accounted for the other half. These results are in agreement with our earlier findings on erythrocytes of a subject with a genetic deficiency of catalase. However, an unexpected result with the present approach was the finding that the increased dependence on the glutathione peroxidase/reductase mechanism did not occur until greater than 98% of the catalase had been inactivated. The latter observation indicates that catalase and the glutathione peroxidase/reductase system function intracellularly in a manner very different from that previously ascribed to them. An explanation of the findings requires that the two methods of H2O2 disposal function in a coordinated way, such as a sequential action in which the glutathione peroxidase/reductase system is the rate-limiting step. 相似文献
59.
60.